PriceTargets.com logo

Cortexyme - CRTX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.05 As of 04/19/2024 01:00 AM ET
▼ -0.01 (-0.94%)

This chart shows the closing price for CRTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cortexyme Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRTX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Cortexyme in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.05.

This chart shows the closing price for CRTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Cortexyme. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/9/2022HC WainwrightLower TargetBuy$30.00 ➝ $15.00High
1/28/2022Canaccord Genuity GroupDowngradeBuy ➝ Hold$75.00 ➝ $12.00High
1/27/2022JMP SecuritiesDowngradeOutperform ➝ Market PerformHigh
10/27/2021Bank of AmericaDowngradeNeutral ➝ Underperform$58.00 ➝ $15.00N/A
10/27/2021HC WainwrightLower TargetBuy$200.00 ➝ $30.00N/A
10/6/2021Needham & Company LLCInitiated CoverageBuyHigh
8/26/2021HC WainwrightReiterated RatingPositive ➝ Buy$76.00 ➝ $200.00High
8/9/2021HC WainwrightReiterated RatingBuy$76.00High
2/16/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$59.00 ➝ $34.00Low
12/11/2020Smith Barney CitigroupInitiated CoverageSellHigh
12/7/2020Bank of AmericaUpgradeNeutral ➝ BuyMedium
9/24/2020Lifesci CapitalReiterated RatingOutperformHigh
6/24/2020HC WainwrightInitiated CoverageBuy$76.00High
6/2/2020Jefferies Financial GroupInitiated CoverageBuy$59.00Low
6/3/2019Credit Suisse GroupInitiated CoverageUnderperform ➝ Underperform$14.00High
6/3/2019Bank of AmericaInitiated CoverageNeutral ➝ Neutral$28.00High
6/3/2019JMP SecuritiesInitiated CoverageMkt Outperform ➝ Mkt Outperform$53.00High
(Data available from 4/20/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/20/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Cortexyme logo
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $1.05
Low: $1.02
High: $1.07

50 Day Range

MA: $1.19
Low: $0.99
High: $1.95

52 Week Range

Now: $1.05
Low: $1.78
High: $40.66

Volume

97,247 shs

Average Volume

620,672 shs

Market Capitalization

$31.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4

Frequently Asked Questions

What sell-side analysts currently cover shares of Cortexyme?

The following Wall Street sell-side analysts have issued stock ratings on Cortexyme in the last year:
View the latest analyst ratings for CRTX.

What is the current price target for Cortexyme?

0 Wall Street analysts have set twelve-month price targets for Cortexyme in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Cortexyme in the next year.
View the latest price targets for CRTX.

What is the current consensus analyst rating for Cortexyme?

Cortexyme currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CRTX.

What other companies compete with Cortexyme?

Other companies that are similar to Cortexyme include Ikena Oncology, Genenta Science, Aligos Therapeutics, Turnstone Biologics and JATT Acquisition. Learn More about companies similar to Cortexyme.

How do I contact Cortexyme's investor relations team?

Cortexyme's physical mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company's listed phone number is (650) 910-5717 and its investor relations email address is [email protected]. The official website for Cortexyme is www.cortexyme.com. Learn More about contacing Cortexyme investor relations.